FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023

AFT Pharma reports growth and global expansion
Read More
FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023
Read More
AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.
Read More
AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.
Read More
AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.
Read More
Independent director Jon Lamb today retired from the board following his announcement at the ASM.
Read More
AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.
Read More
AFT Pharmaceuticals announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested, as it considers registration of the company’s patented intravenous pain relief medicine Maxigesic IV.
Read More
As a result of these launches and recent sales AFT will enter the new financial year with Maxigesic sold in 61 countries in various dose forms, 15 more than where we were in March 2022.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces the US Food and Drug Administration has approved a rapid release tablet form of Maxigesic for the management of mild to moderate acute pain in the US.
Read More
AFT Pharmaceuticals releases New Year letter to shareholders.
Read More
AFT PHARMACEUTICALS LTD FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2022
Read More
AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC).
Read More
AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC).
Read More
AFT Pharmaceuticals today announces that Dr Doug Wilson will step down from its Board of Directors
Read More
AFT Pharmaceuticals and RooLife Group today announce they have launched a range of AFT’s over the counter (OTC) pharmaceuticals through their store on the China Cross Border E-Commerce (CBEC) online platform Tmall Global.
Read More
AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021.
Read More
Farmaforce, an award-winning contract sales organisation offering innovative solutions to the Australian pharmaceutical industry, today confirmed its formal partnership with AFT Pharmaceuticals (AFT) to provide “best in class” representation to healthcare practitioners and professionals.
Read More